Announcement of the 2025 Annual Meeting
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) recently announced the date for its upcoming Annual Meeting of Stockholders, scheduled for October 17, 2025. This meeting serves as a vital opportunity for shareholders to engage with the company and discuss significant matters related to their investment.
Details of the Annual Meeting
The exact time and location of the Annual Meeting will be communicated to stockholders through formal meeting materials. These details will be sent to stockholders recorded as of 5 p.m. Eastern Time on a specific record date, allowing ample time for all interested parties to prepare for attendance.
Understanding the Company’s Bylaws
Eagle’s bylaws lay out important procedural requirements and deadlines that govern how meetings are conducted, including various stipulations applicable to the 2025 Annual Meeting. These bylaws ensure that the meeting is organized, efficient, and oriented towards facilitating shareholder participation.
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals is known for its comprehensive capabilities in the pharmaceutical sector, which encompass research and development, clinical trials, manufacturing, and commercial distribution. The company is dedicated to creating advanced medicines designed to significantly enhance the lives of patients.
Portfolio of Products
The portfolio of Eagle includes a variety of commercialized products, showcasing its commitment to innovation in medicine. Notable offerings comprise PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (available in Japan), along with BYFAVO® and BARHEMSYS®, which are distributed through its subsidiary, Acacia Pharma Inc. The diversity of its product line underscores Eagle’s strengths in managing critical and oncology-related treatments.
Future Focus and Pipeline
Moreover, Eagle Pharmaceuticals is actively developing a robust pipeline of oncology and critical care therapies. These prospects aim to fill gaps in treatment options for various underserved disease areas. By prioritizing research in personalized medicine within cancer care, the company strives to create more effective, targeted treatments.
Investor Relations
For stakeholders interested in more information or engagement opportunities, Eagle Pharmaceuticals has established a dedicated investor relations team. Investors can reach out to Lisa M. Wilson via phone or email for inquiries. Providing transparency and access to information is a fundamental aspect of the company’s approach to shareholder communication.
Contact Information
For direct inquiries, investors are encouraged to contact:
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Frequently Asked Questions
What is the main purpose of Eagle Pharmaceuticals' Annual Meeting?
The Annual Meeting serves to engage shareholders, providing important updates on company performance and strategic direction.
When will Eagle Pharmaceuticals hold its 2025 Annual Meeting?
The 2025 Annual Meeting is scheduled for October 17, 2025.
How can shareholders participate in the Annual Meeting?
Shareholders recorded as of the specified record date will receive notices with details on how to participate.
What products does Eagle Pharmaceuticals offer?
Eagle markets various products, including PEMFEXY®, RYANODEX®, BENDEKA®, and others, focusing on oncology and critical care.
Who can be contacted for investor relations inquiries?
Investors can contact Lisa M. Wilson for inquiries regarding investor relations.